Pharmaceuticals 2013, 6(8), 988-1038; doi:10.3390/ph6080988
Review

Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action

Hematology/Oncology Division, Penn State Hershey Medical Center, Hershey, PA 17033, USA
* Author to whom correspondence should be addressed.
Received: 4 June 2013; in revised form: 30 July 2013 / Accepted: 16 August 2013 / Published: 21 August 2013
(This article belongs to the Special Issue Chemotherapeutic Agents)
PDF Full-text Download PDF Full-Text [1743 KB, uploaded 21 August 2013 15:23 CEST]
Abstract: The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be predictive of efficacy and safety of these chemotherapeutics. In addition, we discuss how alternate pharmaceuticals have been developed in light of a potential lack of response or resistance to a particular chemotherapeutic.
Keywords: colorectal cancer; personalized medicine; genetic polymorphisms

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Kline, C.L.B.; El-Deiry, W.S. Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action. Pharmaceuticals 2013, 6, 988-1038.

AMA Style

Kline CLB, El-Deiry WS. Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action. Pharmaceuticals. 2013; 6(8):988-1038.

Chicago/Turabian Style

Kline, Christina L.B.; El-Deiry, Wafik S. 2013. "Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action." Pharmaceuticals 6, no. 8: 988-1038.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert